10X Genomics
TXG
$76.60
-0.48%
10x Genomics is a life science technology company that develops instruments, consumables, and software for analyzing biological systems at single-cell and spatial resolution, with flagship platforms including Chromium, Chromium X, Visium, and Xenium sold primarily to academic, translational, and biopharmaceutical research customers. The company is a category-defining player in single-cell and spatial biology, having effectively created and led the market for high-throughput single-cell sequencing tools, though it now faces intensifying competition from both established life-science majors and emerging spatial-biology entrants. The current investor narrative has shifted dramatically toward a growth-reacceleration and operating-leverage story: despite a recent quarter of slightly negative reported revenue growth, the stock has staged a parabolic rally as investors position for a Xenium-driven spatial biology inflection, improving consumables mix, and a credible path to sustained profitability. Sentiment is also being shaped by legal developments, including a $4.8 million patent infringement verdict against Parse Biosciences that the market initially greeted with skepticism given the modest near-term financial impact and potential litigation costs. With a high short interest ratio and a small float relative to peers, the stock has become a battleground name where fundamental re-rating and momentum flows are colliding.…
TXG
10X Genomics
$76.60
Related headlines
TXG 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on 10X Genomics's 12-month outlook, with a consensus price target around $52.13 and implied upside of -31.9% versus the current price.
Average Target
$52.13
0 analysts
Implied Upside
-31.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$40 - $70
Analyst target range
TXG is covered by 15 analysts, with a consensus recommendation of "buy" and a recommendation mean of 2.39 (where 1 is strong buy and 5 is strong sell), indicating a moderately bullish but not overwhelmingly enthusiastic stance. The average price target is $52.13, which implies a downside of approximately -31.9% from the current price of $76.60, a striking disconnect that suggests the stock has rallied well beyond where the sell-side community is comfortable. This is a critical signal: when the current price exceeds the consensus target by such a wide margin, it typically means either the analysts are behind the curve and will need to raise targets, or the stock is in a momentum-driven bubble that is detached from fundamental fair value. The consensus EPS estimate for the current year is -$0.17 (range of -$0.177 to -$0.162), confirming that analysts expect the company to remain unprofitable on a GAAP basis, which makes the bullish price action even more dependent on narrative and future expectations rather than current earnings. The target range spans from a low of $40.00 to a high of $70.00, a spread of $30.00 or 75% of the low target, which signals significant disagreement among analysts about the company's trajectory. Notably, even the highest target of $70.00 is below the current price of $76.60, meaning that not a single analyst in the coverage universe has a target that justifies the current valuation, a rare and cautionary configuration. The high target of $70 likely assumes successful Xenium commercialization, accelerating consumables growth, and a path to sustained profitability, while the low target of $40 prices in competitive pressures, slower spatial biology adoption, and continued cash burn. Institutional ratings show a mix of Neutral/Equal Weight actions from Morgan Stanley, Citigroup, Piper Sandler, and JP Morgan, with Buy/Overweight ratings from Canaccord Genuity and Barclays, and no recent upgrades or downgrades, suggesting the analyst community is in a holding pattern while the stock runs. The short ratio of 4.99 indicates that short sellers have not capitulated despite the rally, which could fuel further squeezes but also signals persistent skepticism about the sustainability of the move.
Drowning in data?
Find the real signal!
Bulls vs Bears: TXG Investment Factors
The bull case for TXG rests on its explosive price momentum, recurring consumables revenue, improving profitability, and attractive growth-adjusted valuation, while the bear case highlights the extreme disconnect between the stock price and analyst targets, negative revenue growth, and nosebleed valuation multiples. Currently, the bear evidence appears stronger: the stock trades 47% above the average analyst target, revenue is declining, and the EV/EBITDA of 439x is unsustainable without a sharp earnings recovery. The single most important tension is whether the Xenium spatial biology platform can drive a revenue reacceleration that justifies the current valuation; if it does, the stock could continue higher, but if adoption disappoints, a severe multiple compression is likely. Given the high beta and momentum-driven nature, the risk/reward is skewed to the downside in the near term.
Bullish
- Explosive Price Momentum: TXG has surged 477.24% over the past year and 360.89% year-to-date, massively outperforming the S&P 500's 15.01% and 11.7% respective returns. The stock is trading just 4.2% below its 52-week high of $79.94, signaling strong institutional accumulation and trend persistence.
- Consumables-Driven Recurring Revenue: Consumables contributed $129.80 million, or roughly 86% of product and service revenue in Q1 2026, creating a razor-and-blade model with high recurring revenue. This mix supports gross margins that have remained stable between 67.3% and 72.3% over the past five quarters.
- Improving Profitability and Cash Flow: Net loss narrowed to $13.47 million in Q1 2026 from $34.36 million in Q1 2025, while free cash flow turned consistently positive, totaling $122.18 million on a trailing twelve-month basis. The company holds $490.29 million in cash with a low debt-to-equity ratio of 0.198, providing ample liquidity.
- Attractive Growth-Adjusted Valuation: The PEG ratio of 0.605 suggests the stock is undervalued relative to its growth prospects, and the trailing PS of 3.17x is near the low end of its historical range (compared to 116.13x in Q4 2021). If revenue growth reaccelerates, the multiple could expand significantly.
Bearish
- Price Far Exceeds Analyst Targets: The current price of $76.60 is 47% above the average analyst target of $52.13 and 9.4% above the highest target of $70.00, meaning not a single analyst sees fair value at current levels. This extreme disconnect often precedes a sharp correction as reality sets in.
- Negative Revenue Growth: Q1 2026 revenue declined 2.61% year-over-year to $150.84 million, and the consensus revenue estimate of $879.78 million for the current year implies only flat-to-modest growth. Without a clear reacceleration, the valuation is unsustainable.
- Extreme Valuation Multiples: The EV/Sales of 15.49x and EV/EBITDA of 439.61x are exceptionally high, especially given negative net income and operating margins of -6.77% and -17.25%, respectively. These multiples price in a profitability recovery that has yet to materialize.
- High Volatility and Beta: With a beta of 2.077, TXG is more than twice as volatile as the market, and the stock has experienced a 28.03% maximum drawdown even during its massive uptrend. A 10% market decline could translate into a 20% drop in TXG, posing significant risk for momentum-chasing investors.
TXG Technical Analysis
TXG is in an exceptionally powerful, sustained uptrend that has taken the shares from a 52-week low of $11.16 to a current price of $76.60, a gain of 477.24% over the trailing year and 360.89% year-to-date. At $76.60, the stock is trading at approximately 95.8% of its 52-week range (with the 52-week high at $79.94), meaning it sits just below its absolute peak and is exhibiting classic momentum leadership rather than mean-reversion potential. This positioning near the top of the range signals strong institutional accumulation and trend persistence, but also raises the risk of profit-taking and sharp drawdowns given the stock's beta of 2.077, which implies it is more than twice as volatile as the broader market. The 28.03% maximum drawdown over the period underscores that even within this massive uptrend, investors have endured meaningful corrections. Recent momentum is not only intact but accelerating: the stock is up 23.17% over the past month and 120.40% over the past three months, with the one-month gain actually outpacing the three-month annualized pace and far exceeding the S&P 500's -0.96% one-month return, producing a relative strength of +24.13% versus the index. This acceleration is corroborated by the six-month gain of 316.53% and the fact that the stock has made a series of higher highs through September, closing at $76.60 on September 18 after touching $76.97 the prior session. There is no divergence between short- and long-term trends here; instead, the one-month, three-month, six-month, and one-year timeframes are all aligned in a bullish cascade, which typically signals trend conviction but also late-stage extension risk as the move becomes increasingly vertical. Key technical levels are well defined: immediate resistance sits at the 52-week high of $79.94, and a decisive breakout above that level would likely trigger momentum-chasing flows and open the door to price discovery above $80. Support is anchored at the 52-week low of $11.16, but more relevant near-term support likely lies in the $60-$65 zone where the stock consolidated in late August and early September; a breakdown below $60 would signal a momentum failure and could expose the $50 area. With a beta of 2.077, position sizing should account for the fact that a 10% market decline could translate into a roughly 20% drawdown in TXG, making stop-loss discipline and volatility-adjusted sizing essential.
Beta
2.08
2.08x market volatility
Max Drawdown
-28.0%
Largest decline past year
52-Week Range
$11-$80
Price range past year
Annual Return
+477.2%
Cumulative gain past year
| Period | TXG Return | S&P 500 |
|---|---|---|
| 1m | +23.2% | -0.5% |
| 3m | +120.4% | +2.3% |
| 6m | +316.5% | +16.6% |
| 1y | +477.2% | +14.8% |
| ytd | +360.9% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TXG Fundamental Analysis
TXG's revenue trajectory is showing signs of stabilization after a period of deceleration, with the most recent quarter (Q1 2026, ended March 31, 2026) delivering $150.84 million in revenue, a -2.61% year-over-year decline versus the $154.88 million reported in Q1 2025. However, the sequential trend is more constructive: revenue rose from $149.00 million in Q3 2025 to $166.03 million in Q4 2025 before seasonally dipping to $150.84 million in Q1 2026, and the Q1 2026 figure was actually above the Q1 2025 level on a sequential basis when adjusted for seasonality. The revenue mix is heavily consumables-driven, with consumables contributing $129.80 million (roughly 86% of product and service revenue), instruments at $11.26 million, services at $8.83 million, and licensing/royalty at $0.95 million, meaning the business model is increasingly recurring and razor-and-blade in nature, which should support margin expansion as the installed base grows. The key fundamental debate is whether the Xenium spatial platform can reaccelerate instrument and consumable pull-through enough to return the company to sustained mid-single-digit or better growth, and the analyst consensus revenue estimate of $879.78 million for the current year implies roughly flat-to-modest growth versus the trailing four-quarter run rate. Profitability remains the central issue: TXG reported a net loss of $13.47 million in Q1 2026 (a -8.93% net margin) and an operating loss of $17.05 million (-11.30% operating margin), though this is a dramatic improvement from the -$34.36 million net loss and -22.18% net margin in Q1 2025. Gross margin has been remarkably stable and high, ranging from 67.3% to 72.3% over the past five quarters, with Q1 2026 at 70.39% and Q4 2025 at 68.09%, reflecting the strong pricing power of the consumables franchise. The company's trailing twelve-month net margin is -6.77% and operating margin is -17.25%, but the directional trend is clearly toward breakeven, with the Q2 2025 quarter even posting positive net income of $34.54 million (boosted by a $40.7 million other-expense benefit) and positive operating income of $30.13 million, demonstrating the operating leverage inherent in the model when revenue scales. The balance sheet is a source of strength: TXG carries a debt-to-equity ratio of just 0.198, a current ratio of 4.46, and $490.29 million in cash at the end of Q1 2026, providing ample liquidity to fund operations without external financing. Free cash flow has turned consistently positive, with $24.52 million in Q1 2026, $39.00 million in Q4 2025, $42.53 million in Q3 2025, and $16.13 million in Q2 2025, totaling $122.18 million on a trailing twelve-month basis, which equates to a free cash flow yield of roughly 1.5% on the $8.02 billion market cap (using the higher market cap figure) or about 6.0% on the $2.03 billion market cap figure reported in the key metrics. ROE and ROA remain negative at -5.47% and -5.05% respectively, but the improving FCF profile and high cash balance suggest the company can self-fund its R&D and commercial expansion, with R&D running at $56.85 million in Q1 2026 (37.7% of revenue) and stock-based compensation at $22.64 million, both of which are drags on GAAP profitability but supportive of long-term competitive positioning.
Quarterly Revenue
$150843000.0B
2026-03
Revenue YoY Growth
-2.6%
YoY Comparison
Gross Margin
70.4%
Latest Quarter
Free Cash Flow
$122180000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TXG Overvalued?
Because TXG reported negative trailing net income (-$13.47 million in the most recent quarter and a trailing PE of -46.6), the PE ratio is not meaningful as a primary valuation metric; instead, the PS ratio is the appropriate lead metric, and TXG currently trades at a trailing PS of 3.17x and an EV/Sales of 15.49x. The forward PE of 376.73x is technically positive but reflects a near-breakeven earnings base, making it a poor anchor; the more informative signal is the forward PS implied by the consensus revenue estimate of $879.78 million against the $2.03 billion market cap (roughly 2.3x forward sales) or against the $8.02 billion market cap figure (roughly 9.1x forward sales), depending on which market cap is accurate. The wide gap between trailing PS of 3.17x and the EV/Sales of 15.49x is largely a function of the enterprise value calculation including debt and cash adjustments, and the PEG ratio of 0.605 suggests that on a growth-adjusted basis the stock is not egregiously expensive if the projected growth materializes. Compared to the broader healthcare information services and life science tools sector, where mature peers often trade at 4-8x sales and high-growth genomics names can trade at 10-15x sales, TXG's 3.17x trailing PS looks inexpensive on the surface, but the 15.49x EV/Sales and 439.61x EV/EBITDA suggest the market is pricing in a substantial earnings recovery that has not yet appeared in reported financials. The premium embedded in the EV/EBITDA multiple is extreme and reflects the fact that EBITDA is barely positive on a trailing basis, meaning the multiple is essentially a call option on future profitability rather than a reflection of current cash generation. Historically, TXG's PS ratio has compressed dramatically from nosebleed levels: it traded at 116.13x sales in Q4 2021, 75.05x in Q1 2022, 36.06x in Q4 2023, and 18.06x in Q1 2026, meaning the current 3.17x trailing PS (or 12.48x as of Q4 2025 per historical ratios) is near the low end of its own historical band. This compression reflects both the stock's massive price decline from 2021 highs and the substantial revenue growth over that period, and it suggests that if the company can return to growth, the valuation has significant room to re-rate upward toward its historical mid-cycle multiples. However, the current price of $76.60 is up 477% year-over-year, meaning the market has already begun pricing in that re-rating; the risk is that the stock has run ahead of fundamentals, and any disappointment in Xenium adoption or revenue growth could trigger a sharp multiple compression given the beta of 2.077.
PE
-46.6x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
439.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant despite a strong balance sheet. TXG reported a net loss of $13.47 million in Q1 2026, with operating and net margins of -11.30% and -8.93%, respectively, and trailing twelve-month margins of -17.25% and -6.77%. Revenue declined 2.61% year-over-year in Q1 2026, and the business remains heavily dependent on consumables (86% of product revenue), which ties performance to the installed base of instruments. R&D spending remains high at $56.85 million (37.7% of revenue), and stock-based compensation of $22.64 million further weighs on GAAP profitability, meaning the company must continue to grow revenue to achieve sustainable profitability. While free cash flow is positive at $122.18 million TTM, the trailing PS of 3.17x and EV/Sales of 15.49x suggest the market is pricing in a recovery that may not materialize if growth stalls.
Market and competitive risks are elevated due to the stock's extreme valuation and high beta. TXG trades at an EV/EBITDA of 439.61x and a forward PE of 376.73x, leaving no room for error; any disappointment in Xenium adoption or competitive pressures could trigger a sharp multiple compression. The beta of 2.077 means the stock is highly sensitive to market downturns, and the 28.03% maximum drawdown over the past year illustrates the potential for severe corrections. Competition is intensifying from both established life-science majors and emerging spatial-biology entrants, and the recent $4.8 million patent verdict against Parse Biosciences, while a win, was met with a 5% stock drop, reflecting concerns about legal costs and limited near-term financial impact. Additionally, the high short ratio of 4.99 indicates persistent skepticism that could amplify downside moves if sentiment shifts.
In a worst-case scenario, a combination of slowing Xenium adoption, revenue growth turning negative, and a market rotation away from high-multiple growth stocks could cause TXG to retrace toward its 52-week low of $11.16 or the analyst low target of $40.00. From the current price of $76.60, a drop to $40.00 would represent a 47.8% loss, while a decline to the 52-week low of $11.16 would be an 85.4% loss. Such a scenario could be triggered by a disappointing earnings report, a guidance cut, or a broader market correction that compresses multiples for unprofitable growth stocks. Given the beta of 2.077, a 20% market decline could translate into a 40% drop in TXG, making downside risk substantial.
